UNSPSC 41181529: Alpha-globulin immunological test system

In this classification, a Alpha-globulin immunological test system is a device that consists of the reagents used to identify by immunochemical techniques Alpha-globulin. US FDA regulates Alpha-globulin immunological test system under 21 CFR 866.5400 and under FDA product code DCO.

UNSPSC 41181529 Alpha-globulin immunological test system is a Commodity code that does not map cleanly to the recent state and local procurement activity filed under it. Of the fourteen opportunities in the dataset, only two address laboratory testing services with any relevance to clinical or pathology work: Marion County, Oregon's July 2026 ITB for laboratory testing services and phlebotomy for Adults in Custody (SO1814-26, due July 24, 2026), and the Texas Department of State Health Services' July 2026 IFB for annual maintenance of lab equipment at the South Texas Laboratory in Harlingen (HHS0017421, due July 6, 2026, with historical annual value ranging from $25,050 to $40,000). The remaining twelve opportunities span unrelated categories—water treatment plant construction, electric utility meter testing systems, transit authority ChargePoint charging station maintenance, landscape engineering services, fire station construction materials testing, university research equipment procurement, and sole-source technical support agreements—none of which involve immunological assays, globulin testing, or serological diagnostics.

The code shows sparse recent activity aligned with its nominal scope. Marion County and the Texas Department of State Health Services represent the only state and local buyers pursuing work within the laboratory services domain during the period covered by the dataset. No geographic concentration emerges; Marion County (Oregon) and the Texas Department of State Health Services (Harlingen) appear as isolated instances rather than indicators of active regional demand. The mismatch between the code's immunological assay focus and the equipment maintenance and general phlebotomy services actually being solicited suggests either misclassification of opportunities by issuing bodies or a genuine absence of state and local demand for alpha-globulin test systems and related diagnostic immunology products at the time these opportunities were posted.